

Cipla partners with Stempeutics, launches Stem Cell Therapy for Knee Osteoarthritis

Ciplostem is a disease-modifying approach that slows down disease progression and promotes cartilage maintenance, thereby offering long-term pain relief for Grade II and III Knee OA

Mumbai, December 3, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") has announced the launch of Ciplostem, an innovative allogeneic mesenchymal stromal cell (MSC) therapy for Knee Osteoarthritis (Knee OA), approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine.

Knee OA is a chronic, progressive degenerative joint disease affecting more than 48.4 million people in India as of 2021, with a rising prevalence even among younger populations. Current standard treatments primarily offer short-term relief through painkillers, viscosupplementation, or physiotherapy, often leaving a critical unmet need for therapies that target disease progression.

Ciplostem is a single-dose intra-articular injection (directly into the knee joint) comprising 25 million ex vivo expanded, pooled, cultured adult human bone marrow-derived mesenchymal stem cells (BM-MSCs), co-administered with hyaluronic acid. Designed to work at the cellular level, this therapy reduces inflammation and pain, enhances joint function, and helps preserve cartilage quality for patients with Grade II and III knee osteoarthritis.

Commenting on the launch, **Dr. Jaideep Gogtay, Global Chief Medical Officer, Cipla** said, "At Cipla, our focus continues to remain on moving up the innovation curve and delivering next-generation therapies that improve overall patient outcomes. With Ciplostem, our aim is to bring a scientifically validated cell therapy option into everyday clinical practice, which significantly reduces pain, preserves joint function and enhances mobility for up to 2 years after administration in knee OA."

"At Stempeutics, our efforts have always been focused at developing therapies that address disease fundamentally. Ciplostem sets a new benchmark in regenerative medicine, reflecting years of dedicated research and robust Phase 3 evidence. We are pleased to partner with Cipla to extend the reach of this stem cell therapy in India, transforming scientific innovation into tangible patient impact," added **BN Manohar, MD & CEO, Stempeutics Research**.

Through this launch, Cipla and Stempeutics reaffirm their collective focus on science-driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients' everyday lives.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Aug'25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com

About Stempeutics:

Stempeutics is the leading Regenerative Medicine company in India with CDSCO (Indian FDA-equivalent) approved and marketed: cell-based therapeutic products (Stempeucel®) for three clinical indications. Published data from Phase 1, Phase 2, Phase 3 and Phase 4 trials demonstrate Stempeucel® products are disease-modifying, wherein a single administration leads to clinically meaningful efficacy and durable outcomes. Beyond the approved products, product pipeline comprises of three additional Stempeucel products in late/early-stage human clinical trials. Stempeutics was founded in 2006 based out of innovative stem cell research originating from Manipal Education and Medical Group (MEMG). This research has culminated into proprietary platform (Stempeutics Pooling Technology™) supported by nearly 100 issued patents and filed patent applications world-wide. Stempeutics Pooling Technology™ permits robust, scalable, cost-effective, industrialized manufacture of Stempeucel® products with consistent biological activity and product potency. Stempeutics has marketing partnerships with Cipla for product sales and distribution in India. Stempeutics has also licensed its technology and products for commercial development and marketing in multiple countries outside India. Stempeutics continues to innovate and build upon its

unique technology platform to in future customize biological activity of its therapeutics products for bespoke clinical indications by further engineering of pooled donor derived Mesenchymal Stromal Cells. For more information, please visit www.stempeutics.com

Disclaimer: *The content of this document is only for information and awareness purposes and is not intended nor implied to be construed as a substitute for professional medical advice. This content is not intended towards any product promotion or advertisement. Please consult your doctor for more information.*